(Press-News.org) NEW HYDE PARK, NY - Fifteen year olds are not only able to buy over-the-counter dietary supplements from a sampling of health food stores across the country, the staff at those stores actually went so far as to recommend certain products, despite labels reading "for adult use only."
The American Academy of Pediatrics recommends against using body-shaping supplements -- supplements are unregulated by the US Food & Drug Administration -- for males and females under age 18. Despite the adults-only labeling, it is legal for minors to buy these products in 49 states.
Results of recent studies led by senior investigator Ruth Milanaik, DO, in which testers identifying themselves as 15-year-old boys and girls called 244 health food stores in 49 states (both independently owned and large-chain retailers) will be the focus of three presentations Sunday at the Pediatric Academic Societies meeting in San Diego.
All three studies were conducted by Alexis E Tchaconas, BA; and college students Laura A Fletcher and Maguire Herriman. They were overseen by Andrew Adesman, MD, and Dr. Milanaik, both of Cohen Children's Medical Center in New Hyde Park, NY.
Dr. Milanaik said previous studies have shown the high prevalence of minors using these products -- both athletes and non-athletes. It is the responsibility of all who are in a position to educate minors regarding supplement usage to be knowledgeable of the risks, she said.
Teenagers dealing with negative body images are increasingly turning to over-the-counter supplements, despite recommendations from the American Academy of Pediatrics to avoid such products, Dr. Milanaik said.
.
She warned that health food store supplements are not always healthy, and health food store attendants are not always "experts" when selling well-known "fat burning" thermogenic products (such as Hydroxycut,and Shredzm), testosterone boosters, or products containing creatine.
Despite many testosterone boosters bearing warnings such as "for adult use only," the team found that 41 percent of sales attendants told callers identifying themselves as 15-year-olds they could purchase a testosterone booster on their own. The findings are reported in a study entitled Over-the-Counter Testosterone Boosters and Underage Teens: Easy Access and Misinformation Provided by National Retailers.
Although testosterone boosters are specifically not recommended for children under age 18 unless for documented medical reasons, 9.8 percent of sales attendants recommended a testosterone booster, the study showed.
"Adolescents are being enticed by flashy advertisements and promises of quick, body-shaping results," Dr, Milanaik said. "In this body-conscious world, flashy advertising of `safe, quick and easy body shaping results' are very tempting to younger individuals trying to achieve 'the perfect body.' It is important for pediatricians, parents, coaches and mentors to stress that healthy eating habits, sleep and daily exercise should be the recipe for a healthy body."
"Health food stores that advertise that their employees are 'trained experts' need to re-educate their employees and reinforce that these products are not recommended for minors," Dr. Milanaik.
Despite the AAP's statement that the use of weight-loss supplements is unhealthy for minors, sales attendants at health food stores frequently recommend these products to underage female teens looking to lose weight, according to the third study: Weight Loss and Underage Teens: Supplement Recommendations from National Retailers
Dr. Milanaik said that all of the research drives home the fact that parents and teens should not assume that products coming from health food or vitamin stores are safe or recommended for minors.
"Health food stores need to focus not only on knowing what products to recommend," said Laura Fletcher, one of the principal investigators, "but often more importantly, what products not to recommend for customers of certain ages and conditions."
The products in the study, Hydroxycut, Shredz and testosterone boosters, often carry specific warnings that state "for adult-use only," Dr. Milanaik said. These warnings reflect research that has previously documented adverse health effects for growing minors.
"In the instance where warnings are clearly printed on supplement bottles," Ms. Fletcher said, "sales attendants must be aware of the dangers associated with underage use. The goal of ridding adolescents of body image-related insecurity in a healthy, supportive and medically-approved environment needs to be prioritized."
Health food store supplements do not always equal healthy, and health food store attendants are not always "experts," Dr. Milanaik added.
INFORMATION:
"All products should be checked for safety warnings regardless of who recommends the product. If in doubt, call your doctor and/or consult the AAP website (http://www.HealthyChildren.org)."
To schedule an interview with Dr.Milanaik before or during the PAS meeting, call 516-633-7416 or email RLMilanaik@Yahoo.com.
No outside funding was received for this research.
About the Steven and Alexandra Cohen Children's Medical Center of New York
Opened in 1983, the Steven and Alexandra Cohen Children's Medical Center of New York is home to about 675 pediatricians, including 200 full-time physicians, and a total workforce of more than 1,200, including more than 500 nurses. For the eighth consecutive year in 2014, CCMC was ranked among the best children's hospitals in the nation in U.S. News & World Report's 2014-15 "America's Best Children's Hospitals" survey.
SAN DIEGO - Pediatric research discoveries over the past 40 years haveled to prevention and treatment strategies that have saved millions of lives worldwide. Seven of the greatest research achievements will be presented on Sunday, April 26 at the Pediatric Academic Societies annual meeting at the San Diego Convention Center.
"Today, we often take these research discoveries for granted," said presenter Tina Cheng, MD, MPH, FAAP, chair of the American Academy of Pediatrics Committee on Pediatric Research. "Because of research and science in these seven areas, American ...
April 25, 2015, Vienna, Austria: New data presented today at The International Liver Congress™ 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT). The results are based on data from patients with HCV being treated with second-generation DAAs in the large French prospective ANRS CO23 CUPILT study. Among them, 296 patients were treated with a combination of SOF+DCV, with or without ribavirin.
SOF- and DCV-based regimens offered high rates of ...
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks ...
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.
The study found that chronic HCV infection has a limited impact on mortality, unless the patient also has other severe comorbidities, such as HIV infection, cancer or chronic kidney disease. In contrast, those with AUDs are at significant risk of death with a higher ...
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.
Overall, the sustained virologic response rate at 4 weeks (SVR4) for SOF/DCV was 81.6% after 12 weeks of treatment and 93.9% ...
April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence.
ALLY-1 ...
April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...
April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults ...
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...